Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy

三阴性乳腺癌 乳腺癌 医学 癌症研究 CD8型 基因签名 CXCR3型 免疫疗法 T细胞 免疫系统 肿瘤科 内科学 免疫学 癌症 生物 趋化因子 基因表达 基因 趋化因子受体 生物化学
作者
Melinda L. Telli,Hiroshi Nagata,Irene Wapnir,Chaitanya R. Acharya,Kaitlin Zablotsky,Bernard A. Fox,Carlo Bruno Bifulco,Shawn M. Jensen,Carmen Ballesteros‐Merino,Mai Hope Le,Robert Hamilton Pierce,Erica Browning,Reneta Hermiz,Lauren Svenson,Donna Bannavong,Kim Jaffe,Jendy Sell,Kellie Malloy Foerter,David A. Canton,Chris Twitty
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:27 (9): 2481-2493 被引量:70
标识
DOI:10.1158/1078-0432.ccr-20-3944
摘要

Abstract Purpose: Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Antibodies targeting programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in TNBC, but only a minority of patients benefit. A way to reliably enhance immunogenicity, T-cell infiltration, and predict responsiveness is critically needed. Patients and Methods: Using mouse models of TNBC, we evaluate immune activation and tumor targeting of intratumoral IL12 plasmid followed by electroporation (tavokinogene telseplasmid; Tavo). We further present a single-arm, prospective clinical trial of Tavo monotherapy in patients with treatment refractory, advanced TNBC (OMS-I140). Finally, we expand these findings using publicly available breast cancer and melanoma datasets. Results: Single-cell RNA sequencing of murine tumors identified a CXCR3 gene signature (CXCR3-GS) following Tavo treatment associated with enhanced antigen presentation, T-cell infiltration and expansion, and PD-1/PD-L1 expression. Assessment of pretreatment and posttreatment tissue from patients confirms enrichment of this CXCR3-GS in tumors from patients that exhibited an enhancement of CD8+ T-cell infiltration following treatment. One patient, previously unresponsive to anti–PD-L1 therapy, but who exhibited an increased CXCR3-GS after Tavo treatment, went on to receive additional anti–PD-1 therapy as their immediate next treatment after OMS-I140, and demonstrated a significant clinical response. Conclusions: These data show a safe, effective intratumoral therapy that can enhance antigen presentation and recruit CD8 T cells, which are required for the antitumor efficacy. We identify a Tavo treatment-related gene signature associated with improved outcomes and conversion of nonresponsive tumors, potentially even beyond TNBC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被走四方采纳,获得10
1秒前
1秒前
1秒前
彪壮的语芙完成签到 ,获得积分10
1秒前
上官若男的应助被WU_JIABIN采纳,获得10
2秒前
Orange的应助被学术bug采纳,获得10
2秒前
tx的应助被Gigang采纳,获得10
3秒前
3秒前
3秒前
syvshc的应助被瞿qks采纳,获得10
3秒前
3秒前
一个弟弟完成签到,获得积分10
3秒前
谦让忆枫发布了新的文献求助30
4秒前
红雨瓢泼发布了新的文献求助20
4秒前
wei完成签到,获得积分10
4秒前
晚风发布了新的文献求助10
5秒前
科研助理795的应助被nuanyang采纳,获得10
5秒前
6秒前
夏沫完成签到,获得积分10
6秒前
Eva完成签到,获得积分10
6秒前
7秒前
7秒前
lele完成签到,获得积分20
7秒前
华无剑的应助被阿瑞采纳,获得10
8秒前
天青色完成签到,获得积分10
9秒前
白鸽乐章完成签到,获得积分10
9秒前
lfunnnnn发布了新的文献求助10
9秒前
可爱的函函的应助被StewieIU采纳,获得10
9秒前
爆米花的应助被xiaozhang采纳,获得10
10秒前
冰淇淋完成签到,获得积分10
10秒前
10秒前
ui24发布了新的文献求助10
11秒前
LIUDAN发布了新的文献求助10
11秒前
汉堡包的应助被yanifang采纳,获得10
11秒前
瞬间发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
吉尼斯贝贝完成签到,获得积分10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178866
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805411
捐赠科研通 7774048
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478628